Echosens and Boehringer Ingelheim have expanded their collaboration aimed at expediting progress in metabolic dysfunction-associated steatohepatitis (MASH) diagnosis and care.
The joint effort seeks to address the critical need for early screening and diagnosis as MASH becomes a leading cause of liver failure globally.
Go deeper with GlobalData
The combination of Echosens and Boehringer Ingelheim’s diagnostic and therapeutic capabilities is set to bridge gaps in awareness, evidence and clinical practice.
Their combined initiatives will emphasise patient education, healthcare professional engagement, policy advocacy, streamlined care pathways adoption and broaden access to non-invasive technologies.
MASH is a chronic liver condition linked with obesity that can progress silently to a severe stage without intervention.
Boehringer Ingelheim head of the therapeutic area for cardiovascular, renal and metabolic Sandy Sommer stated: “For too long, serious liver diseases like MASH have gone under the radar — but with MASH rates soaring alongside the global obesity epidemic, it’s time to tackle liver disease head on.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“Obesity and MASH are deeply interconnected chronic diseases that no organisation can tackle alone. At Boehringer, we’re committed to being part of the solution, and the expansion of our partnership with Echosens is one we’re particularly excited about.”
Echosens’ FibroScan, a non-invasive liver assessment technology, has been instrumental in supporting Boehringer Ingelheim’s Survodutide Phase III trials by facilitating patient screening and monitoring.
Survodutide combines glucagon-like peptide-1 (GLP-1) with glucagon receptor agonists for MASH and related metabolic disorders such as obesity.
Boehringer Ingelheim holds global responsibility for the development and commercialisation of Survodutide after licensing it from Zealand Pharma.
It forms part of the company’s broader research and development efforts focusing on cardiovascular, renal and metabolic diseases.
In May 2025, Boehringer partnered Tempus AI to develop a cancer therapy pipeline.
